Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universidad Nacional De La Pampa currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is being conducted by 1 distinct examiner, indicating a focused and singular engagement with the patent office. The university's current intellectual property activity in this sector is concentrated on this 1 active matter, reflecting a specific research or development focus.
The activity is situated within 1 distinct art unit, which suggests that the technology is specialized. GALSTER, SAMUEL LEONARD is the busiest examiner for this portfolio, currently managing 1 pending office action. As the only examiner involved, their evaluation is the primary factor in the current prosecution of the university's Biotechnology & Pharmaceuticals applications.
For practitioners, the presence of 1 distinct examiner and 1 distinct art unit simplifies the administrative aspects of the prosecution. With only 1 pending office action in total, the university can dedicate its resources to addressing the specific requirements of GALSTER, SAMUEL LEONARD. This streamlined environment in the Biotechnology & Pharmaceuticals field allows for a targeted strategy to resolve the 1 pending office action currently on record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705349 | GLYCOCONJUGATED DRUG FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | GALSTER, SAMUEL LEONARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705349 | GLYCOCONJUGATED DRUG FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705349 | GLYCOCONJUGATED DRUG FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | GALSTER, SAMUEL LEONARD | 1693 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversidad Nacional De La Pampa has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samuel Leonard Galster has the most, with 1 of Universidad Nacional De La Pampa's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
